A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement

Phase 1 Recruiting 40 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of HDM1002

Timeline

Start: 2025-03-18
Primary completion: 2026-01-14
Completion: 2026-05-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HDM1002	Unknown	—	—

Indications

No indication recorded.